Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

Biohaven has started a randomised Phase II/III trial of the TYK2 / JAK1 inhibitor, BHV-8000, aimed at treating early ...

Zilovertamab vedotin, an antibody drug conjugate (ADC) developed by Merck & Co (MSD) to treat diffuse large B-cell lymphoma ...

Auron has dosed the first subject in the Phase I trial of AUTX-703, targeting individuals with advanced haematologic ...

After Lykos' rejection from the FDA last year, companies trying to navigate the psychedelic drug trial sector face various ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Intellia's news comes at a challenging time for gene therapies, as multiple serious adverse events and fatalities have been ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

GSK plans to submit to the US Food and Drug Administration (FDA) for regulatory approval of tebipenem HBr by the end of 2025.

Experts discuss the use of artificial intelligence (AI) and patient-centric strategies in oncology clinical trials.

Merck KGaA is filing for global regulatory approvals of pimicotinib after it met primary and secondary endpoints in a Phase ...

Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary ...